Gildan Activewear Reaches New 52-Week High (GIL)

NEW YORK ( TheStreet) -- Gildan Activewear (NYSE: GIL) hit a new 52-week high Tuesday as it is currently trading at $37.97, above its previous 52-week high of $37.92 with 613,710 shares traded as of 3:36 p.m. ET. Average volume has been 488,300 shares over the past 30 days.

Gildan Activewear has a market cap of $4.4 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 29.9% year to date as of the previous trading day's close.

Gildan Activewear Inc. manufactures and sells T-shirts, activewear, underwear, and socks to wholesale screen printers, embroiderers, and retailers in North America, Europe, and internationally. It sells T-shirts, fleece, and sport shirts under the Gildan brand name. The company has a P/E ratio of 21.2, below the average consumer non-durables industry P/E ratio of 21.4 and above the S&P 500 P/E ratio of 16.2.
  • Practice your GIL trading strategies and win cash in our stock game.

TheStreet Ratings rates Gildan Activewear as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Gildan Activewear Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing